 | Today's Top Story |  |  | | - Breaking down the list of biopharma's most influential
Leaders of big drugmakers, including Sanofi, Roche and GlaxoSmithKline, make up the biggest contingent in the FiercePharma list of the 25 most influential people in biopharma. Also present on the list are executives at small biotechs, philanthropist Bill Gates, investor Dietmar Hopp and researchers Craig Venter and Bob Langer. Forbes (2/19)       | Gene Location Affects Properties, Impacts on Regulatory Pathways | | Boston – Location, location, location: The idea that one gene equals one protein is long discredited and research into mechanisms including post-translational modification proteins and the baroque complexities of epigenetic control is advancing understanding of how one gene can generate multiple proteins. Find out the details. |  |
- Firms ally to develop plant-based drugs
Caliber Biotherapeutics and iBio agreed to jointly develop and produce recombinant plant-based biopharmaceuticals using Caliber's plant-based production expertise and the iBioLaunch platform. The partners will initially work on a monoclonal antibody for cancer. iBio will get license and milestone fees and sales royalties on products arising from the collaboration. Genetic Engineering & Biotechnology News (2/19) - Gilead's hep C drug sofosbuvir hits primary goal in 4th Phase III trial
Hepatitis C patients who took Gilead Sciences' sofosbuvir had cure rates of 50% at 12 weeks and 73% at 16 weeks for genotypes 2 and 3, compared with a 25% historic cure rate with other drugs, data from a late-stage trial showed. "With positive results from all four Phase 3 trials now in hand, Gilead is on track to meet its goal of filing regulatory applications in the United States and Europe in the second quarter," Gilead Chief Scientific Officer Norbert Bischofberger said. Yahoo/Reuters (2/19) - Obama administration to unveil 10-year brain-mapping project
The Obama administration is looking to unveil next month a 10-year project to map the active human brain, called Brain Activity Map. Scientists say the project may pave the way for the development of technologies that will help improve understanding of neurological conditions such as Alzheimer's and Parkinson's disease. The project, which may be worth $3 billion over 10 years, may also allow for the creation of national brain "observatories," akin to astronomical observatories. The New York Times (tiered subscription model) (2/17)  | Learn More About What Engineering Management Can Do For You
Engineering Management is the MBA alternative for engineers, scientists and technical professionals who want to move into management. The University of Colorado Boulder offers online courses, certificates, and degrees to meet your educational needs. Or, just subscribe to our free e-newsletter to keep up with industry trends. Learn More or Subscribe |
 | Company & Financial News | | | | - Isis gets $7.5 million from GSK for antisense drug trial
GlaxoSmithKline is paying Isis Pharmaceuticals a $7.5 milestone fee for launching a Phase II/III trial of ISIS-TTRRx, an experimental antisense drug for transthyretin amyloidosis. The partners plan to use the results of the trial to support an application for marketing approval in patients with familial amyloid polyneuropathy. RTT News (2/19) | Food & Agriculture | | | | - Report: Biotech crop acreage grows to new high
The total global planted area of biotech crops reached 170.3 million hectares in 2012, 10.3 million hectares more than in the previous year, according to a report from the International Service for the Acquisition of Agri-Biotech Applications. Growers who used biotech seeds numbered 17.3 million, an increase of 600,000. The U.S. remains the top grower of biotech crops with 69.5 million hectares of planted area, followed by Argentina and Canada. Reuters (2/19) | Industrial & Environmental | | | | - Startup, university to research heat-tolerant fungus for biofuel
Sustainable Bioproducts is partnering with Montana State University to study the biofuel potential of heat-tolerant fungus from Yellowstone National Park's hot springs that converts the cellulose in algae into oil. "The most important part of our research now is to test the technology further and investigate the feasibility of using this organism to produce biofuels and other products," said company founder Mark Kozubal. The National Science Foundation has awarded an initial grant of $150,000 to the venture. Biofuels-News.com (U.K.) (2/18)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | We must travel in the direction of our fear."
--John Berryman,
American poet and scholar  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, February 19, 2013
- Monday, February 18, 2013
- Friday, February 15, 2013
- Thursday, February 14, 2013
- Wednesday, February 13, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment